Mackay Shields LLC’s Coherus Oncology CHRS Stock Holding History

Mackay Shields LLC’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,600	Closed	-$416K	–	1474
2020 Q1	$416K	Buy	+25,600	New	+$473K	﹤0.01%	1166

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Mackay Shields LLC's CHRS Position: Q2 2020 in Review

Mackay Shields LLC sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 25,600 shares — an estimated $416K sold.

Mackay Shields LLC first reported a position in CHRS in Q1 2020 and held it in 1 quarter. The position peaked at $416K in Q1 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

Mackay Shields LLC reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
Mackay Shields LLC sold 25,600 Coherus Oncology shares in Q2 2020, an estimated $416K.
Mackay Shields LLC first reported a position in Coherus Oncology in Q1 2020 and held it in 1 quarter.
Mackay Shields LLC's Coherus Oncology position peaked at $416K in Q1 2020.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Mackay Shields LLC's 13F filing for Q2 2020, filed 31 Jul 2020.